Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.54 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.54 |
| ▸ | ACE | P12821 | 6/20 | 0.52 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.51 |
| ▸ | MME | P08473 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.50 |
| ▸ | CPA1 | P15085 | 1/20 | 0.49 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.49 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | ALB | P02768 | 1/20 | 0.47 |
| ▸ | IL2 | P60568 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1081373 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL31533362 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL31533361 | 1.00 | FOLH1 (0.54) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL246177 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL20726 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL23704504 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL29746410 | 0.87 | FOLH1 (0.51) | FOLH1NAALAD2ACESLC7A5MME | |
| SCHEMBL626035 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 | |
| SCHEMBL4880143 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 | |
| SCHEMBL5560323 | 0.86 | MME (0.54) | FOLH1NAALAD2ACEMMEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | claimed |
| US-20090232853-A1 | TREATMENT OF LAMINITIS | MARS UK LIMITED (GB) | 2009-09-17 | — | — | US | claimed |
| EP-1863573-A1 | TREATMENT OF LAMINITIS | MARS UK LIMITED (GB) | 2007-12-12 | — | — | EP | claimed |
| WO-2006100468-A1 | TREATMENT OF LAMINITIS | MARS UK LIMITED (GB) | 2006-09-28 | — | — | WO | claimed |
| WO-2025034906-A1 | HIGHLY SPECIFIC BLOOD-BASED BIOMARKER OF PARKINSON'S DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2025-02-13 | — | — | WO | disclosed |
| WO-2024072905-A1 | NOVEL BIOMARKERS IN PARKINSON'S DISEASE | THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) | 2024-04-04 | — | — | WO | disclosed |
| US-20240033366-A1 | FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF | INSTITUT CURIE (FR) | 2024-02-01 | — | — | US | disclosed |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | SENDA BIOSCIENCES INC (US) | 2023-06-15 | — | — | US | disclosed |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE | 2023-06-08 | — | — | US | disclosed |
| WO-2021216781-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-10-28 | — | — | WO | disclosed |
| US-20210332396-A1 | GENETIC ELEMENTS IN ENTEROCOCCUS SPP. TO PRODUCE DOPAMINE | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2021-10-28 | — | — | US | disclosed |
| CN-112752740-A | Process for the preparation of fluoromethyl-18 labelled radiopharmaceutical agents using selective azide substitution and precursor scavenging | BIK治疗公司 | 2021-05-04 | — | — | CN | disclosed |
| WO-2006100468-A1 | TREATMENT OF LAMINITIS | MARS UK LIMITED (GB) | 2006-09-28 | — | — | WO | disclosed |
| EP-0451422-A1 | Pharmaceutically active fluoromethyltyrosine compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| EP-0451422-A1 | Pharmaceutically active fluoromethyltyrosine compounds | MERRELL DOW PHARMACEUTICALS INC. (US) | 1991-10-16 | — | — | EP | disclosed |
| US-4695588-A | DECARBOXYLASE INHIBITORS | MERCK & CO., INC. (US) | 1987-09-22 | — | — | US | disclosed |
| EP-0040150-B1 | FLUOROMETHYLATED TYROSINE METHYL ESTER | MERRELL TORAUDE ET COMPAGNIE (FR) | 1983-09-21 | — | — | EP | disclosed |
| US-4325961-A | FLUOROMETHYLHISTIDINE, ESTERS, AND SALTS | MERCK & CO., INC. (US) | 1982-04-20 | — | — | US | disclosed |
| US-4288601-A | A-FLUOROMETHYL AMINO ACIDS FROM THE A-HYDROXYMETHYL COMPOUND USING SULFUR TETRAFLUORIDE AND BORON TRIFLUORIDE IN HYDROFLUORIC ACID | MERCK & CO., INC. (US) | 1981-09-08 | — | — | US | disclosed |
| US-4215221-A | A-FLUOROMETHYL AMINO ACIDS FROM THE A-HYDROXYMETHYL COMPOUNDS USING SULFUR TETRAFLUORIDE IN HYDROFLUORIC ACID AND ALUMINUM CHLORIDE | MERCK & CO., INC. (US) | 1980-07-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240033366-A1 | FUNCTIONALIZED SHIGA TOXIN B-SUBUNIT (STxB) PROTEINS AND CONJUGATES THEREOF | STXBP1, STX18, SCTR | FOLH1 1884/4885NAALAD2 1721/4885ACE 2684/4885 |
| US-20230174460-A1 | AFMT ANALOGS AND THEIR USE IN METHODS OF TREATING PARKINSON'S DISEASE | PARK7, SNCA, RHOT2 | FOLH1 547/4885NAALAD2 996/4885ACE 3108/4885 |
| US-20230181493-A1 | BIOMARKERS RELATED TO PARKINSON'S DISEASE AND METHODS OF USING THE SAME | COMT, SNCA, PARK7 | FOLH1 60/4885NAALAD2 159/4885ACE 669/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.